CL2015002181A1 - Tratamiento de formas progresivas de esclerosis múltiple con laquinimod. - Google Patents
Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.Info
- Publication number
- CL2015002181A1 CL2015002181A1 CL2015002181A CL2015002181A CL2015002181A1 CL 2015002181 A1 CL2015002181 A1 CL 2015002181A1 CL 2015002181 A CL2015002181 A CL 2015002181A CL 2015002181 A CL2015002181 A CL 2015002181A CL 2015002181 A1 CL2015002181 A1 CL 2015002181A1
- Authority
- CL
- Chile
- Prior art keywords
- laquinimod
- multiple sclerosis
- treatment
- progressive forms
- progressive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361765394P | 2013-02-15 | 2013-02-15 | |
| US201361911106P | 2013-12-03 | 2013-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015002181A1 true CL2015002181A1 (es) | 2016-06-03 |
Family
ID=51351655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002181A CL2015002181A1 (es) | 2013-02-15 | 2015-08-05 | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140235670A1 (enExample) |
| EP (1) | EP2956137A4 (enExample) |
| JP (1) | JP2016510343A (enExample) |
| KR (1) | KR20150119227A (enExample) |
| CN (1) | CN105163737A (enExample) |
| AU (1) | AU2014216199A1 (enExample) |
| BR (1) | BR112015019564A2 (enExample) |
| CA (1) | CA2900503A1 (enExample) |
| CL (1) | CL2015002181A1 (enExample) |
| EA (1) | EA201591507A1 (enExample) |
| HK (2) | HK1218254A1 (enExample) |
| IL (1) | IL240014A0 (enExample) |
| MX (1) | MX2015010296A (enExample) |
| PE (1) | PE20151526A1 (enExample) |
| SG (1) | SG11201505818WA (enExample) |
| TW (1) | TW201442709A (enExample) |
| UY (1) | UY35328A (enExample) |
| WO (1) | WO2014127139A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| TW201804997A (zh) * | 2012-05-02 | 2018-02-16 | 以色列商泰瓦藥品工業有限公司 | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
| HK1231413A1 (zh) | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| CA2964315A1 (en) * | 2014-10-16 | 2016-04-21 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| US10091217B2 (en) | 2016-06-21 | 2018-10-02 | Logrhythm, Inc. | Risk based priority processing of data |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| IL316573A (en) * | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| WO2022011155A1 (en) * | 2020-07-09 | 2022-01-13 | Oklahoma Medical Research Foundation | Biomarkers for identifying relapses in multiple sclerosis |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| CN101466379B (zh) * | 2006-06-12 | 2012-10-31 | 泰华制药工业有限公司 | 稳定的拉喹莫德的制剂 |
| CA2693697C (en) * | 2007-07-11 | 2017-07-25 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| EP2375900B1 (en) * | 2008-12-11 | 2016-03-02 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
| NZ597378A (en) * | 2009-06-19 | 2014-08-29 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| PE20140872A1 (es) * | 2010-12-07 | 2014-08-09 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple |
| HK1198278A1 (en) * | 2011-07-28 | 2015-03-27 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| TW201804997A (zh) * | 2012-05-02 | 2018-02-16 | 以色列商泰瓦藥品工業有限公司 | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
| MX2015004564A (es) * | 2012-10-12 | 2015-07-21 | Teva Pharma | Laquinimod para producir el daño talamico en la esclerosis multiple. |
| HK1231413A1 (zh) * | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
-
2014
- 2014-02-13 KR KR1020157024953A patent/KR20150119227A/ko not_active Withdrawn
- 2014-02-13 HK HK16106269.3A patent/HK1218254A1/zh unknown
- 2014-02-13 CA CA2900503A patent/CA2900503A1/en not_active Abandoned
- 2014-02-13 AU AU2014216199A patent/AU2014216199A1/en not_active Abandoned
- 2014-02-13 US US14/180,173 patent/US20140235670A1/en not_active Abandoned
- 2014-02-13 EA EA201591507A patent/EA201591507A1/ru unknown
- 2014-02-13 BR BR112015019564A patent/BR112015019564A2/pt active Search and Examination
- 2014-02-13 EP EP14751103.4A patent/EP2956137A4/en not_active Withdrawn
- 2014-02-13 JP JP2015558130A patent/JP2016510343A/ja active Pending
- 2014-02-13 PE PE2015001745A patent/PE20151526A1/es not_active Application Discontinuation
- 2014-02-13 MX MX2015010296A patent/MX2015010296A/es unknown
- 2014-02-13 WO PCT/US2014/016278 patent/WO2014127139A1/en not_active Ceased
- 2014-02-13 SG SG11201505818WA patent/SG11201505818WA/en unknown
- 2014-02-13 CN CN201480009035.XA patent/CN105163737A/zh active Pending
- 2014-02-13 HK HK16106220.1A patent/HK1218251A1/zh unknown
- 2014-02-14 UY UY0001035328A patent/UY35328A/es not_active Application Discontinuation
- 2014-02-14 TW TW103104987A patent/TW201442709A/zh unknown
-
2015
- 2015-07-19 IL IL240014A patent/IL240014A0/en unknown
- 2015-08-05 CL CL2015002181A patent/CL2015002181A1/es unknown
-
2017
- 2017-11-13 US US15/811,139 patent/US20180064702A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015010296A (es) | 2016-05-05 |
| HK1218254A1 (zh) | 2017-02-10 |
| HK1218251A1 (zh) | 2017-02-10 |
| TW201442709A (zh) | 2014-11-16 |
| US20140235670A1 (en) | 2014-08-21 |
| EP2956137A1 (en) | 2015-12-23 |
| KR20150119227A (ko) | 2015-10-23 |
| IL240014A0 (en) | 2015-09-24 |
| BR112015019564A2 (pt) | 2017-07-18 |
| US20180064702A1 (en) | 2018-03-08 |
| WO2014127139A1 (en) | 2014-08-21 |
| EA201591507A1 (ru) | 2015-12-30 |
| AU2014216199A1 (en) | 2015-09-03 |
| PE20151526A1 (es) | 2015-11-20 |
| JP2016510343A (ja) | 2016-04-07 |
| CA2900503A1 (en) | 2014-08-21 |
| UY35328A (es) | 2014-09-30 |
| EP2956137A4 (en) | 2016-08-03 |
| CN105163737A (zh) | 2015-12-16 |
| SG11201505818WA (en) | 2015-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151526A1 (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod | |
| UY34720A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fumarato de dimetilo | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| EA201690753A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
| CL2016000042A1 (es) | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. | |
| GT201600027A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| PL3229794T3 (pl) | Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego | |
| EP3177311C0 (en) | COMBINATION OF MEDICINAL PRODUCTS CONTAINING CABOZANTINIB AND A PROTEASOME INHIBITOR FOR THE TREATMENT OF MULTIPLE MYELOMA | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX365321B (es) | Métodos para el tratamiento de neutropenia mediante agonistas retinoides. | |
| UY34786A (es) | Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo | |
| EA201691108A1 (ru) | Хиназолин-thf-амины в качестве ингибиторов pde1 | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| PT3228313T (pt) | Formas de dosagem e utilizações terapêuticas de l-4-cloroquinurenina | |
| CL2015002666A1 (es) | Formas de dosificación sólidas de antiemético de liberación prolongada | |
| UY35823A (es) | Profármacos de antagonista de nmda | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| EA201690446A1 (ru) | Лечение множественной миеломы | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. | |
| BR112015016394A2 (pt) | carboxamidas ii baseadas em pirazolil como inibidoras do canal crac | |
| GEAP202014778A (en) | Combination of trazodone and gabapentin for the treatmen | |
| BR112015019792A2 (pt) | composição para tratamento de hemorróidas e método de preparação | |
| AR094809A1 (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| LT2988782T (lt) | Dozavimo formos, skirtos peroraliniam veikliųjų medžiagų vartojimui |